Kratom Research Institute

Safety · 2026-08-27

Case Report: High-Dose Buprenorphine-Naloxone Successfully Manages Severe 7-OH Withdrawal in VA Patient

Source: Primary Care Companion for CNS Disorders

Why it matters

This peer-reviewed case report documents severe opioid-level withdrawal from commercially sold 7-OH products and shows that standard buprenorphine protocols may be inadequate — requiring doses up to 40 mg in the first 24 hours. Clinicians treating kratom and 7-OH patients need to know this.

The big picture

As 7-OH products spread into retail markets, emergency departments and inpatient units are encountering patients with severe opioid withdrawal who may not disclose their use. Unlike fentanyl, 7-OH does not typically show on standard urine drug screens, creating a diagnostic blind spot. This case, published from the Minneapolis VA Health Care System, illustrates exactly how that blind spot plays out in real clinical settings.

Key findings

What they say

"This case highlights the potent opioid properties and risk of dependence and withdrawal associated with 7-OH. We encourage clinicians to specifically inquire about 'seven-o' when the use of kratom is reported," wrote authors Jacob T. Held, PharmD, BCPP, and Francisco P. Varicat, DO, both of the Minneapolis VA Health Care System.

Bottom line

Patients using high-dose 7-OH products can experience opioid withdrawal as severe as fentanyl users, and standard buprenorphine protocols may need to be significantly scaled up — clinicians should ask about '7-OH' specifically, as patients often don't volunteer it.